Cite

HARVARD Citation

    Hajek, R. et al. (2020). A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. European journal of haematology. pp. 435-442. [Online]. 
  
Back to record